Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a report released on Wednesday, November 13th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings of ($0.88) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $53.00 target price on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals' Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.90) EPS and Q4 2025 earnings at ($0.91) EPS.
Other research analysts also recently issued reports about the company. William Blair upgraded Xenon Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Wedbush reduced their target price on Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating on the stock in a research report on Friday, August 9th. Raymond James reissued an "outperform" rating and issued a $50.00 price target on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. Eleven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $57.45.
Check Out Our Latest Research Report on XENE
Xenon Pharmaceuticals Stock Down 4.6 %
Shares of NASDAQ:XENE traded down $1.92 during trading on Friday, reaching $39.83. The stock had a trading volume of 654,007 shares, compared to its average volume of 387,176. The stock has a market cap of $3.04 billion, a P/E ratio of -14.21 and a beta of 1.25. The business has a fifty day moving average price of $41.18 and a 200-day moving average price of $40.36. Xenon Pharmaceuticals has a fifty-two week low of $28.10 and a fifty-two week high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter last year, the company posted ($0.73) earnings per share.
Institutional Trading of Xenon Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC lifted its stake in shares of Xenon Pharmaceuticals by 2.2% during the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company's stock worth $272,349,000 after purchasing an additional 149,511 shares in the last quarter. Driehaus Capital Management LLC raised its holdings in shares of Xenon Pharmaceuticals by 2.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 4,419,472 shares of the biopharmaceutical company's stock valued at $172,315,000 after buying an additional 97,732 shares during the period. Wellington Management Group LLP lifted its position in Xenon Pharmaceuticals by 0.4% during the 3rd quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company's stock worth $151,317,000 after acquiring an additional 15,226 shares in the last quarter. Braidwell LP boosted its holdings in Xenon Pharmaceuticals by 5.7% in the 3rd quarter. Braidwell LP now owns 2,707,255 shares of the biopharmaceutical company's stock worth $106,585,000 after acquiring an additional 146,682 shares during the period. Finally, Janus Henderson Group PLC grew its position in Xenon Pharmaceuticals by 144.2% in the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock valued at $100,506,000 after acquiring an additional 1,507,135 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Read More
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
